Fundz

Tharimmune

Bridgewater, New Jersey, United States · Biotechnology, Health Care, Therapeutics · 2 employees

Tharimmune, Inc. (NASDAQ: THAR) is the first publicly traded company to leverage Canton Coin and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets. In addition to driving value through activities on the Canton Network, Tharimmune also operates clinical-stage biotech research and development.

Funding history

  • Series seed — $1.7M — Apr 2026
  • Series seed — $1.2M — Apr 2026
  • Funding Round — $540.0M — Nov 2025
  • Series seed — $2.5M — Jul 2025
  • Series seed — $2.0M — Dec 2024

Recent signals

  • Apr 15, 2026: Raised $1.7M in Series seed
  • Apr 15, 2026: Raised $1.2M in Series seed
  • Feb 06, 2026: Tharimmune Appoints Angela Radkowski as Chief Operating Officer
  • Nov 07, 2025: SEC 8-K (5.02): On November 7, 2025, Tharimmune, Inc. appointed Sireesh Appajosyula as interim Chief Financial Officer. This appointment is set to last until December 31, 2025, and is part of the company's efforts to ensure effective management and financial oversight during this transitional period. Mr. Appajosyula's existing employment agreement with the company continues to remain in effect, indicating continuity in his role despite the interim nature of this appointment. This change may impact the strategic direction of the company, particularly in financial decision-making as they approach year-end.
  • Nov 04, 2025: Raised $540.0M
  • Nov 03, 2025: SEC 8-K (1.01): On November 3, 2025, Tharimmune, Inc. entered into securities purchase agreements with certain accredited investors as part of a private placement offering. The agreements involve the sale of an aggregate of shares of common stock at an offering price of $3.075 per share, as well as pre-funded warrants to purchase additional shares. This capital raising effort aims to strengthen the company's financial position. The exact total amount raised through this offering has not been disclosed in the filing, but it indicates significant engagement with investors to enhance liquidity and fund operations.
  • Jul 07, 2025: Raised $2.5M in Series seed
  • Dec 17, 2024: Raised $2.0M in Series seed

See plans & pricing → Track Tharimmune’s funding, hiring, and signals — with verified contacts — on Fundz.